This study has demonstrated the feasibility of using the DTP regimen for the treatment of HER2-positive breast cancer, showing comparable pCR rates and DFS rates between neoadjuvant DTP and the standard AC-taxan/TP treatments. Here, ERBB2 is linked to breast carcinoma.